- Animalcare Group - a leading supplier of veterinary medicines - expects its results for the year to the end of June to be broadly in line with recently revised expectations.

It said trading in companion animal identification products and services remains difficult.

But some progress has been made in the launch of new products and services using the modernised registration database.

Revenue for this product group will be slightly better than indicated in the May trading update, but still approximately 29% below those for year ending 30 June 2011. Revenue for the full year from the group's core licensed veterinary medicines segment remained strong.

Excluding the impact of the temporary disruption to the supply of Buprecare ampoules, revenue in this segment is approximately 17% ahead of last year.

When the effects of the supply disruption are included, revenue for the segment was approximately 2% ahead of last year. The group's target of four new licensed veterinary medicines launches in the financial year was passed with a total of five products launched.

At 8:15am: [LON:ANCR] share price was 0p at 130p

Story provided by